Alcon Inc. Reports Q3 2026 Growth Driven by Vision Care and Surgical Equipment
Alcon Inc. (ALC) reported third-quarter net sales of $2.7 billion, a 5% increase driven by strong momentum in its Vision Care and Surgical segments. The company saw significant growth in surgical equipment and ocular health products, including the Systane franchise. Despite these gains, the implantables segment experienced a 2% decline due to competitive pressures within the U.S. premium intraocular lens market. Financial performance was bolstered by core gross margin expansion to 65.7%, aided by manufacturing efficiencies and nonrecurring tariff refunds. While Alcon updated its full-year 2026 guidance for revenue, margins, and EPS to narrower ranges, the company remains focused on long-term growth through strategic acquisitions like Neurotech and restructuring efforts aimed at generating $130 million in annual savings.
Tickers: $ALC
Topics: Gross Margin Net Sales Operating Margin Surgical Segment Vision Care Segment